Related Experiment Videos
Gonadal endocrine dysfunction in patients with lung cancer: relation to responsiveness to chemotherapy, respiratory
U Aasebø1, R M Bremnes, A Aakvaag
1Department of Chest Medicine, University Hospital of Tromsø, Norway.
Abstract:
Male lung cancer patients with poor performance status [Eastern Cooperative Oncology Group (ECOG) index 3-4] have an endocrinological dysfunction as assessed by serum testosterone and sex hormone-binding globulin (SHBG) levels. Patients who respond to therapy regain normal free testosterone levels within 12 weeks post chemotherapy, whereas non-responders continue to exhibit subnormal levels. The perturbations of endocrinological variables in patients with lung cancer is not due to development of hypoxia, as patients with respiratory failure maintain a significantly lower testosterone level compared to cancer patients. The development of a deficiency in total testosterone concentrations in lung cancer patients is correlated to their performance status, and not to the presence of metastatic disease. The mechanisms responsible for the endocrinological dysfunction in patients with lung cancer remain unknown.
Insights
Male lung cancer patients with poor performance status experience endocrinological dysfunction, specifically low testosterone. Therapy response correlates with testosterone normalization, independent of hypoxia or metastasis.
Area of Science:
- Endocrinology
- Oncology
- Medical Research
Background:
- Male lung cancer patients often exhibit endocrinological dysfunction.
- Performance status, specifically Eastern Cooperative Oncology Group (ECOG) index 3-4, is linked to hormonal imbalances.
Purpose of the Study:
- To investigate endocrinological dysfunction in male lung cancer patients.
- To assess the relationship between testosterone, sex hormone-binding globulin (SHBG), and lung cancer characteristics.
Main Methods:
- Serum testosterone and SHBG levels were measured in male lung cancer patients.
- Hormonal levels were analyzed in relation to performance status, chemotherapy response, hypoxia, and metastatic disease.
Main Results:
- Poor performance status (ECOG 3-4) was associated with endocrinological dysfunction, including low testosterone and SHBG levels.
- Responders to chemotherapy showed normalized free testosterone levels within 12 weeks, unlike non-responders.
- Testosterone deficiency correlated with performance status, not hypoxia or metastatic disease.
Conclusions:
- Endocrinological dysfunction, particularly testosterone deficiency, is prevalent in male lung cancer patients with poor performance status.
- Chemotherapy response influences testosterone recovery.
- The underlying mechanisms of this hormonal dysfunction in lung cancer patients require further investigation.